Medical Pharmaceuticals

Another Hisense HD60 Ultrasound Installation at Vaal Radiology, South Africa

by

CAPE TOWN, South Africa, May 19, 2023 /PRNewswire/ — Hisense, a manufacturer and provider of high-performance electronics and medical devices, has recently installed the Hisense Ultrasound HD60 at Vaal Radiology, a medical imaging center in Vereeninging, South Africa. This color Doppler ultrasound system is ideal for various ultrasound applications including general abdominal, vascular, and small parts. … Read more

10 Stories You Need to See

by

A roundup of the week’s most newsworthy health industry press releases from PR Newswire, including the FDA approval of a medication to moderate hot flashes. NEW YORK, May 19, 2023 /PRNewswire/ — With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists … Read more

Optellum’s Clinical Partners Present at ATS International Conference 2023

by

Clinicians from top US healthcare centers demonstrate the benefits of AI-assisted early lung cancer diagnosis at this year’s American Thoracic Society (ATS) International Conference WASHINGTON, May 19, 2023 /PRNewswire/ — Optellum, a medtech company that provides a ground-breaking AI platform to diagnose and treat early-stage lung cancer, is attending this year’s American Thoracic Society International Conference … Read more

RZNOMICS Inc. received FDA approval to initiate clinical development of trans-splicing ribozyme-based RNA editing technology in Glioblastoma Multiforme Patients

by

SEONGNAM, South Korea, May 19, 2023 /PRNewswire/ — Rznomics Inc., a South Korea based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, recently received Phase 1/2a IND approval from the U.S FDA on May 6th for its Glioblastoma Multiforme (GBM) treatment called RZ-001 and thus has achieved an important milestone for the company and … Read more

Study Shows PulseAI’s Deep Learning Algorithm Outperforms the Apple Watch ECG Algorithm in Detecting Atrial Fibrillation

by

BELFAST, Northern Ireland, May 19, 2023 /PRNewswire/ — PulseAI, a leader in the development of cutting-edge AI-powered ECG software, has released the results of a clinical study that has shown the superiority of its deep learning AI over the Apple Watch ECG algorithm in the detection of atrial fibrillation (AF). The study was conducted by a … Read more

ExoCoBio obtained a US Patent for Rose Stem Cell-derived Exosome (RSCE™)

by

–  The first plant stem cell-derived exosome patent in the US –  The 5th patent allowance following 3 in Korea and 1 in Japan –  An important milestone for the global plant stem cell-derived exosome industry SEOUL, South Korea, May 19, 2023 /PRNewswire/ — ExoCoBio, one of the top three exosome companies in the world, … Read more

Positive Results from Interim Analysis of ‘GEN-001’ Plus avelumab (Bavencio®) Phase II Trial

by

SEOUL, South Korea, May 19, 2023 /PRNewswire/ — Genome & Company (CEO: Pae, Jisoo), a global leading microbiome therapeutics developer, announced that this phase II trial (NCT05419362) will continue without modifications to move on to the second stage, based on the positive result of the interim analysis. Using a single-strain bacteria in combination with avelumab (Bavencio®) … Read more

EMA validates marketing authorisation application for efanesoctocog alfa for treatment of haemophilia A

by

STOCKHOLM, May 19, 2023 /PRNewswire/ — Sobi today announced that the European Medicines Agency (EMA) has accepted and validated a marketing authorisation application for efanesoctocog alfa, a new class of high-sustained FVIII developed for the treatment of people with haemophilia A of all age groups. The application is based on data from the pivotal XTEND-1 … Read more

EMA validates marketing authorisation application for efanesoctocog alfa for treatment of haemophilia A

by

STOCKHOLM, May 19, 2023 /PRNewswire/ — Sobi today announced that the European Medicines Agency (EMA) has accepted and validated a marketing authorisation application for efanesoctocog alfa, a new class of high-sustained FVIII developed for the treatment of people with haemophilia A of all age groups. The application is based on data from the pivotal XTEND-1 … Read more

EuroPCR 2023 | 6 Month Outcome of the SMART Study: satisfactory BP control achieved with reduced medication burden

by

PARIS, May 19, 2023 /PRNewswire/ — On May 17th 2023, the six-month result of the SMART Study (Sympathetic Mapping/Ablation Renal nerves for Treatment of hypertension Trial; NCT02761811) was released on the Late Breaking Clinical Trial conference, reporting ground-breaking findings in the field of hypertension. With Professor Huo Yong as the leading investigator and SyMap Medical (Suzhou) … Read more